SB15

aflibercept biosimilar · Samsung Bioepis Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SB15, covering 2024-02-05 to 2024-02-05. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

See pricing